EKF Diagnostics (EKF) Share Price, News & Analysis

Company Overview

EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; DiaSpect Hemoglobin T analyzer; Hemo Control, a hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers' milk; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company provides clinical chemical analyzers, such as Beta-hydroxybutyrate for monitoring ketosis; Glycated Albumin; Glycated Serum Protein; Nitro-tab Ketone tablets; and Procalcitonin marker for bacterial infection and sepsis, as well as reagents, calibrators, standards, and controls. Additionally, it offers RaPET Serology immunoassay kits; QuStick Strep A for Strep A infection treatment; Altair 240, a chemistry analyzer; Excel, a semi-automated chemistry analyzer; Micro 12, a micro centrifuge for clinical, molecular, and bacteriological applications; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; Uri-Trak 120 urine analyzer; and kits and other services related to COVID-19, as well as contract manufacturing solutions to third-party businesses and laboratory services. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.

Key Stats

• Today's Range: 25.13 to 26.30
• 50-Day Range: 25 to 30.90
• 52-Week Range: 23 to 34
• Volume: 60,390 shs
• Average Volume: 392,754 shs
• Market Capitalization: £116.61 million
• P/E Ratio: 2,570.00
• Dividend Yield: 3.89%
• Price Target: N/A
• Consensus Rating: N/A

EKF Stock Analysis - Frequently Asked Questions

How have EKF shares performed this year?

EKF Diagnostics' stock was trading at GBX 31.65 at the beginning of 2024. Since then, EKF shares have decreased by 18.8% and is now trading at GBX 25.70.
View the best growth stocks for 2024 here.

How do I buy shares of EKF Diagnostics?

Shares of EKF stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of EKF Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that EKF Diagnostics investors own include ERBA Diagnostics (ERBA), boohoo group (BOO), Lloyds Banking Group (LLOY), 888 (888), Abcam (ABC), ASOS (ASC) and Babcock International Group (BAB).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: N/A
• Current Symbol: LON:EKF
• CUSIP: N/A
• CIK: N/A
• Web: www.ekfdiagnostics.com
• Phone: +44-29-20710570
• Fax: N/A
• Employees: 356
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX 0.01
• Trailing P/E Ratio: 2,570.00
• Forward P/E Ratio: 11.18
• P/E Growth: N/A
• Net Income: £4.78 million
• Net Margins: 9.37%
• Pretax Margin: N/A
• Return on Equity: 7.58%
• Return on Assets: 5.27%

Debt

• Debt-to-Equity Ratio: 1.78
• Current Ratio: 4.59
• Quick Ratio: 1.77

Sales & Book Value

• Annual Sales: £50.95 million
• Price / Sales: 2.29
• Cash Flow: GBX 2.42 per share
• Price / Cash Flow: 10.64
• Book Value: GBX 15 per share
• Price / Book: 1.71

Miscellaneous

• Outstanding Shares: 453,730,000
• Free Float: N/A
• Market Cap: £116.61 million
• Optionable: Not Optionable
• Beta: 0.57